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Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent decrease in the extent 
of activation of superoxide production and of granule secretion, induced by phorbol-lZmyristate-13-acetate (PMA) or 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (WLF). The same treatment also causes a significant reduction in the 
degree of PMA- and fMLF-stimulated phosphorylation of several cell proteins. These include the proteins of 43-47 kDa, 
whose extent of phosphorylation correlates with the activation of superoxide production and of secretion. Contrary to 
the effects exerted on protein phosphorylation, CRP does not affect the fMLF-elicited increase in neutrophil cytosolic 
Ca2+. 
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1. INTRODUCTION 
C-reactive protein is the prototype acute-phase 
. 
serum protein, whose concentration increases from 
a median of 1 pug/ml in healthy subjects up to 
lOOO-fold during inflammatory situations [ 11. 
Although CRP can influence some functions of 
lymphocytes [2] and macrophages [3], neutrophils 
are the most likely target of CRP. Actually, deposi- 
tion of CRP mainly occurs in vivo at inflammatory 
sites infiltrated with neutrophils [4-61, and several 
reports have demonstrated CRP/neutrophil inter- 
actions in vivo [5] and in vitro (7-121. Binding of 
CRP to neutrophils [9-111 appears to play a dual 
role. At concentrations 9 1 pg/ml, CRP elicits 
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neutrophil chemotaxis and phagocytosis, whereas 
at higher concentrations it can inhibit superoxide 
production and secretion [ 121. 
To gain more insight into the latter CRP effects, 
we have attempted to correlate its inhibitory effect 
on superoxide generation and secretion with two 
known neutrophil regulatory mechanisms: protein 
phosphorylation by protein kinases [ 131, and Ca*+ 
mobilization [14]. We have used as stimulants 
PMA, which activates PK-C [ 151, and fMLF, a 
more relevant physiological stimulant, which acts 
via specific receptors [16]. 
2. MATERIALS AND METHODS 
2.1. Preparation of C-reactive protein 
CRP was purified from acute-phase sera as described [12]. 
2.2. Stimulation of 32P-leaded neutrophils 
Neutrophils (B 95%), isolated from human venous blood as 
in [12], were suspended in 20 mM Hepes, brought to pH 7.4 
with NaOH at 37°C. containing 120 mM NaCl. 5 mM KCI. 
0.5 mM MgS04 and 5 mM glucose (buffer Aj. Neutrophil 
suspensions in buffer A with 0.2% BSA (5 x 106/ml) were in- 
cubated for 60-90 min at 37°C with carrier-free Hz3’P04 
(1 mCi/ml) (Radiochemical Centre, Amersham, England). 
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After washing twice with buffer A, the neutrophils were re- 
suspended at 1.5 x 106/ml in the same buffer, supplemented 
with 1 mM CaClz [17]. 
Pre-loaded neutrophils (3 x 106), in a final volume of 
0.25 ml, were treated for 2 min with either lo-’ M fMLF 
(Sigma, St. Louis, USA) in the presence of 5 pg/ml of cyto- 
chalasin B (Serva, Heidelberg), or 20 ng/ml of PMA (Sigma), 
or for 5 min with 0.3-lOO~g/ml of CRP. In the case of 
treatments with fMLF or PMA, appropriate controls were run 
containing cytochalasin B and the stimulant solvent dimethyl 
sulfoxide (final concentration 0.1070). Alternatively, neutrophils 
were incubated with CRP (0.3-100 pg/ml) for 5 min and then 
challenged with either fMLF or PMA for a further 2 min. The 
reaction was stopped with 0.1 ml of 21% (w/v) trichloroacetic 
acid and the precipitated proteins were collected by centrifuga- 
tion and solubilized in Laemmli sample buffer as described [17]. 
When necessary, pH was restored to 6.8 with a few microliters 
of concentrated NaOH. 
2.3. Separation of proteins by SDS-PAGE and 
autoradiography 
After SDS-PAGE, the gels were fixed, stained, dried and sub- 
jected to autoradioeraphy as in [17]. The grey level images of 
bands in autoradiographic films were analyzed automatically by 
the IBAS 2000 system (Kontron, Zurich). The integrated absor- 
bances (IA) of the images are proportional to the extent of [3zP]- 
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Fig.1. Effect of CRP on superoxide production. Neutrophils 
were preincubated with CRP for 5 min, then subsequently 
challenged with either 20 ng/ml PMA (n--O) or 10m7 M 
fMLF (O--O), for a further 5 min. Control values (lOOa, cor- 
responding to 4.5 + 0.3 nmol superoxide/106 neutrophils per 
min) refer to cells treated with stimulants in the absence of CRP. 
Data are means rt SE (PMA, 8 experiments; fMLF, 5 ex- 
periments). Cells were also preincubated with BSA (1 mg/ml) 
and subsequently challenged with fMLF (O--O); mean of two 
experiments. 
phosphorylation [17]. The IAs of [32P]phosphoproteins of cells, 
stimulated either with PMA or fMLF with or without pre- 
treatment with 100 /g/ml CRP, were divided by the values ob- 
tained from unstimulated cells. This provided an estimation of 
both the enhancement in protein phosphorylation caused by 
neutrophil stimulation and the effects of pre-treatment with 
CRP on this process. 
2.4. Superoxide production and secretion 
Superoxide production and secretion of vitamin B12-binding 
protein were determined as previously described [12]. 
2.5. Measurement of intracellular Cd’ 
Measurement of cytosolic Ca2+ was performed with the Ca2+ 
fluorescent probe fura [ 181 as previously described [ 191. 
3. RESULTS 
3.1. Superoxide production and secretion 
Preincubation of neutrophils with increasing 
amounts of CRP (0.3-lOOpg/ml) for 5 or 10 min, 
followed by exposure to either fMLF (lo-’ M) or 
PMA (20 ng/ml) resulted in an increasing inhibi- 
tion of superoxide production up to 40-50% 
(fig.1). Addition of CRP (lOO,ug/ml) together 
with, or following the stimulant resulted in lower 
inhibition, < 20%. The presence of BSA did not 
significantly alter the inhibitory effect of CRP 
a b c d 
Fig.2. Effect of CRP on secretion of vitamin Blz-binding pro- 
tein. Neutrophils were preincubated with CRP (5-10 min) and 
then subsequently challenged with fMLF 10e7 M (15 min). (a) 
fMLF alone; (b-d) 1, 10 or 50 fig/ml CRP, followed by fMLF. 
Hatched areas: no addition of WLF. Data are means of at least 
three experiments f SE. 
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Fig.3. Protein phosphorylation in 32P-labelled human neutro- 
phils treated with PMA (20 ng/ml) and CRP (lOOpg/ml) as 
characterized by SDS-PAGE (10% acrylamide). (a-e) 
Coomassie blue stain, (al-e’) autoradiograph. Lanes: (a,a’) 
control, 2 min (7 min incubation was similar); (b,b’) CRP, 
5 min; (c,c’) PMA, 2 min; (d,d’) preincubation with CRP for 
5 min, followed by addition of PMA for 2 min; (e,e’) PMA and 
CRP incubated together with cells for 7 min. 
(fig. l), suggesting that an excess of another serum 
protein does not block the action of CRP. Prein- 
cubation of neutrophils with CRP also inhibited 
the secretion of vitamin Bi2-binding protein in- 
duced by fMLF (fig.2). 
3.2. Phosphorylation of neutrophil proteins 
Activation of neutrophils with PMA or fMLF 
increased the phosphorylation of several proteins, 
most notably the 66,47 and 43 kDa bands, as com- 
pared to the absence of stimulant (fig.3, lane c vs a; 
fig.4, lane b vs a; and table 1). Cytochalasin B, in- 
cluded in the fMLF reaction medium, had no effect 
on protein phosphorylation per se. CRP 
(100 kg/ml) alone, as compared to the control, in- 
hibited phosphorylation of at least the 66, 47 and 
43 kDa proteins (fig.3, lane b vs a). 
Preincubation for 2 min with CRP (100 fig/ml) 
for 5 min, followed by a challenge with either 
PMA (fig.3, lane d) or fMLF (fig.4, lane c), 
resulted in a marked inhibition of the stimulant- 
Fig.4. Protein phosphorylation in 32P-labelled human neutro- 
phils treated with fMLF (lo-’ M) and CRP (lC@~g/ml) as 
characterized by SDS-PAGE (8-18% linear gradient of acryl- 
amide). (a-c) Coomassie blue stain, (a’-~‘) autoradiograph. 
Lanes: (a,a’) control, 2 min (7 min incubation was similar); 
(b,b’) fMLF, 2 mitt; (c,c’) preincubation with CRP for 5 min, 
followed by addition of fMLF for 2 min. 
enhanced phosphorylation of several proteins (data 
of Coomassie-stained gels exclude the possibility 
that this decrease is due to reduced protein loading 
on gels). These included the proteins of approx. 85, 
66, 54, 47 and 43 kDa (table 1). CRP added 
together (fig.3, lane f) or 2 min after (not shown) 
the stimulant had only a negligible effect on the 
stimulant-enhanced phosphorylation. 
3.3. Phosphorylation of CRP 
In some of the above autoradiographs a phos- 
phorylated protein band of 24 kDa was observed, 
which was superimposed on the CRP band in the 
Coomassie-stained gels. This suggests that CRP 
was exposed to a kinase when incubated with the 
neutrophils. Binding assays performed at 37°C 
have shown an extremely fast binding and inter- 
nalization of CRP [ 111. In a cell-free system, phos- 
phorylation of CRP was achieved only in the 
presence of activated PK-C, but not of CAMP- 
dependent protein kinase (unpublished). 
175 
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Table 1 
Effect of a CRP pretreatment on the phosphorylation of some 
proteins in neutrophils stimulated with PMA or fMLF 
Protein Neutrophil treatment 
PMA fMLF 
- CRP + CRP - CRP + CRP 
85 kDa 1.92 jz 0.33 1.07 +0.17 1.70; 2.53 1.41; 1.33 
66 kDa 3.03 f 0.44 1.26 +0.26 2.73; 3.06 1.40; 1.75 
54 kDa 1.78 + 0.10 0.86 + 0.15 1.70; 3.74 1.04; 1.96 
47 kDa 4.13 + 1.33 1.77 + 0.12 2.61; 4.67 1.91; 1.80 
43 kDa 6.35 t 1.42 3.28 f 0.60 7.75; 4.43 2.27; 1.98 
Experimental conditions as in figs 3,4. Numbers are ratios of in- 
tegrated absorbances of images corresponding to the [“‘Plphos- 
phorylated protein bands in autoradiographic films 
(stimulated/resting cells; see section 2), and are means + SE (5 
experiments) for PMA and two separate xperiments for fMLF 
3.4. CRP and mobilization of intracellular Cd* 
Incubation of neutrophils with CRP neither af- 
fected the basal level of intracellular Ca2+ nor, 
upon preincubation, inhibited the kinetics and ex- 
tent of the fMLF induced increase in intracellular 
Ca2+ (not shown). 
4. DISCUSSION 
Neutrophil functional responses are largely in- 
hibited in cells obtained from synovial fluid, ther- 
mal injury sites, and from experimentally inflam- 
matory sites [20-221. The rate of superoxide pro- 
duction by exudate neutrophils is decreased when 
compared with peripheral blood neutrophils from 
the same donor [23]. In all these situations, CRP 
would be expected to be elevated at the site of 
neutrophil accumulation, its level corresponding to 
the degree of inflammation. The ‘defects’ observed 
in neutrophil function may thus result from ex- 
posure and interaction of the cells with CRP at the 
inflammatory site, as also suggested by the effects 
of the in vitro exposure of neutrophils to CRP 
before stimulation with fMLF (here described) or 
PMA or concanavalin A [ 121. 
In neutrophils as well as in many other cell types, 
the consequences of ligand-receptor interactions 
have been shown to result mainly in an increased 
turnover of phosphatidylinositol and possibly 
phosphatidylcholine, changes in intracellular Ca2+ 
and activation of protein kinases [13,14,17,19, 
24-301. In particular, activation of PK-C and sub- 
176 
sequent phosphorylation of specific proteins, such 
as the cytosolic proteins of 43 and 46-47 kDa, has 
been suggested as an important regulatory 
mechanism in neutrophil activation [13,17,24,27, 
281. This enzyme is normally localized in the 
cytosol and becomes fully active after translocation 
to the plasma membrane [27], where phosphatidyl- 
serine, diacylglycerol and Ca2+ synergise to ac- 
tivate the translocated enzyme. 
In the attempt to understand the molecular 
mechanism(s) by which CRP may inhibit the 
neutrophil response, we have exposed neutrophils 
to CRP before the stimulants PMA or fMLF and 
have observed that this causes a marked inhibition 
of phosphorylation of several proteins including 
those of g&66,54,47 and 43 kDa. Actually the ex- 
tent of inhibition by CRP of phosphorylation of 
some of these proteins, notably the PK-C substrate 
of 47 kDa [17,24], appears to exceed the degree of 
inhibition of neutrophil functions. This, however, 
is in accordance with the concept that neutrophil 
activation may involve not only the activation of 
PK-C, but also of other pathways dependent on 
Ca2+ [13]. In this connection, it is important to 
point out that CRP does not affect the kinetics and 
extent of cytosolic Ca2+ rise in neutrophils ac- 
tivated with fMLF. 
The observed inhibition of phosphorylation of 
some proteins, including those whose phosphoryla- 
tion correlates with neutrophil activation [ 13,17, 
24,25,27], may suggest a mode of action of CRP. 
One possibility might be that this protein slows 
down the turnover of diacylglycerol-generating 
phospholipids [30], also in the absence of effects in 
the calcium rise [3 I]. CRP inhibition of platelet ag- 
gregation has actually been shown to be accom- 
panied by an inhibition of arachidonic acid release 
from both phosphatidylinositol and phosphatidyl- 
choline, suggesting that phospholipases are in- 
hibited [32]. Furthermore, we have demonstrated 
that in neutrophils, CRP increases CAMP concen- 
tration [12], which under some circumstances may 
inhibit phospholipase C [33]. This postulated 
mechanism, however, does not apply to the inhibi- 
tion by CRP of protein phosphorylation in neutro- 
phils treated with PMA, which directly activates 
PK-C [15] without the concurrence of phos- 
phatidylinositol breakdown. An alternative target 
of CRP might thus be a critical step in the mem- 
brane translocation/activation of PK-C. Prelimi- 
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nary experiments, carried out to prove this hypo- 
thesis, have actually indicated that preincubation 
of neutrophils with 100 pg/ml CRP almost totally 
prevents the PMA-induced translocation of PK-C 
to the membrane fraction. 
An intriguing aspect of the CRP action on 
neutrophils is the actual cell compartment where 
CRP interacts with its molecular targets causing 
the metabolic and functional inhibition. We have 
previously shown that CRP binding to neutrophils 
at 37°C and pH 7.4 is saturable, very fast and ex- 
hibits a dissociation constant of 3.3 x 10e8 M [I I]. 
The present studies have also demonstrated that 
CRP, once bound to neutrophils, is available to a 
protein kinase. Furthermore, ‘*‘I-labelled CRP, 
bound to neutrophils, is not extracted by a non- 
ionic detergent (Triton X-100), which removes a 
large fraction of the plasma membrane and all the 
soluble cytoplasm (unpublished), suggesting that it 
may be associated to detergent-insoluble cell struc- 
tures such as the cytoskeleton. The possibility thus 
exists that CRP acts on neutrophils intracellularly, 
under conditions where the components of signal 
transmission and metabolic pathways are fully ac- 
cessible. 
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